Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Oct;59(10):1516-1523.
doi: 10.2967/jnumed.117.206490. Epub 2018 Apr 6.

Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study

Affiliations
Clinical Trial

Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study

Hebert Alberto Vargas et al. J Nucl Med. 2018 Oct.

Abstract

18F-fluorodihydrotestosterone (18F-FDHT) is a radiolabeled analog of the androgen receptor's primary ligand that is currently being credentialed as a biomarker for prognosis, response, and pharmacodynamic effects of new therapeutics. As part of the biomarker qualification process, we prospectively assessed its reproducibility and repeatability in men with metastatic castration-resistant prostate cancer. Methods: We conducted a prospective multiinstitutional study of metastatic castration-resistant prostate cancer patients undergoing 2 (test/retest) 18F-FDHT PET/CT scans on 2 consecutive days. Two independent readers evaluated all examinations and recorded SUVs, androgen receptor-positive tumor volumes, and total lesion uptake for the most avid lesion detected in each of 32 predefined anatomic regions. The relative absolute difference and reproducibility coefficient (RC) of each metric were calculated between the test and retest scans. Linear regression analyses, intraclass correlation coefficients (ICCs), and Bland-Altman plots were used to evaluate repeatability of 18F-FDHT metrics. The coefficient of variation and ICC were used to assess interobserver reproducibility. Results: Twenty-seven patients with 140 18F-FDHT-avid regions were included. The best repeatability among 18F-FDHT uptake metrics was found for SUV metrics (SUVmax, SUVmean, and SUVpeak), with no significant differences in repeatability among them. Correlations between the test and retest scans were strong for all SUV metrics (R2 ≥ 0.92; ICC ≥ 0.97). The RCs of the SUV metrics ranged from 21.3% (SUVpeak) to 24.6% (SUVmax). The test and retest androgen receptor-positive tumor volumes and TLU, respectively, were highly correlated (R2 and ICC ≥ 0.97), although variability was significantly higher than that for SUV (RCs > 46.4%). The prostate-specific antigen levels, Gleason score, weight, and age did not affect repeatability, nor did total injected activity, uptake measurement time, or differences in uptake time between the 2 scans. Including the most avid lesion per patient, the 5 most avid lesions per patient, only lesions 4.2 mL or more, only lesions with an SUV of 4 g/mL or more, or normalizing of SUV to area under the parent plasma activity concentration-time curve did not significantly affect repeatability. All metrics showed high interobserver reproducibility (ICC > 0.98; coefficient of variation < 0.2%-10.8%). Conclusion: Uptake metrics derived from 18F-FDHT PET/CT show high repeatability and interobserver reproducibility.

Keywords: FDHT; PET; prostate cancer; repeatability; reproducibility.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Box plots of percentage differences on lesion level between test and retest scans for several quantitative uptake values. Effect of normalizing to AUCpp is shown.
FIGURE 2.
FIGURE 2.
Bland–Altman plots showing repeatability SUVmax on lesion (A) and patient (B) level. Blue = center 1; red = center 2; green = center 3.
FIGURE 3.
FIGURE 3.
Bland–Altman plots showing repeatability of SUVpeak on lesion (A) and patient (B) level. Blue = center 1; red = center 2; green = center 3.
FIGURE 4.
FIGURE 4.
Bland–Altman plots showing influence of ARTV on repeatability of SUVmax on lesion level. Log scale is used on x-axis. Blue = center 1; red = center 2; green = center 3.
FIGURE 5.
FIGURE 5.
Bland–Altman plots showing repeatability of TLU (A and B) and ARTV (C and D) on lesion (A and C) and patient (B and D) level. For TLU and lesion-level ARTV: log scale is used on x-axis. Blue = center 1; red = center 2; green = center 3.
FIGURE 6.
FIGURE 6.
Box plots of percentage differences on patient level between test and retest scans for several quantitative uptake values. Effect of normalizing to AUC is shown.
FIGURE 7.
FIGURE 7.
Scatterplot showing effect of differences in uptake time (mins) between test and retest scans on differences in uptake at patient level. Similar patterns are seen for other quantitative uptake metrics. Blue = center 1; red = center 2; green = center 3.

References

    1. Huggins C, Hodges CV. Studies on prostatic cancer: I—the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168:9–12. - PubMed
    1. Graham L, Schweizer MT. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Med Oncol. 2016;33:44. - PubMed
    1. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366–373. - PubMed
    1. Zanzonico PB, Finn R, Pentlow KS, et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med. 2004;45:1966–1971. - PubMed
    1. Beattie BJ, Smith-Jones PM, Jhanwar YS, et al. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med. 2010;51:183–192. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources